Cargando…

ProGRP as early predictive marker of non–small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment

We report a case of non–small-cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) transformation after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The patient was a man who diagnosed with EGFR-mutant advanced NSCLC. After he was introduced afatinib, his tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Yasuhiro, Tanaka, Yosuke, Hino, Mitsunori, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468187/ https://www.ncbi.nlm.nih.gov/pubmed/31016132 http://dx.doi.org/10.1016/j.rmcr.2019.100837

Ejemplares similares

Plasma proGRP Concentration is Sensitive and Specific for Discriminating Small Cell Lung Cancer from Nonmalignant Conditions or Non-small Cell Lung Cancer
por: Kim, Hye-Ran, et al.
Publicado: (2011)

Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
por: Wojcik, Ewa, et al.
Publicado: (2017)

Evaluating the diagnostic and prognostic value of serum TuM2‐PK, NSE, and ProGRP in small cell lung cancer
por: Li, Li, et al.
Publicado: (2023)

Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report
por: Oya, Yuko, et al.
Publicado: (2018)

Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs
por: Tian, Kui, et al.
Publicado: (2022)

Detection of Changes in CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and the Relationship with CT Signs
por: Huang, Jingshan, et al.
Publicado: (2023)

Utility of the Serum ProGRP Level for Follow-up of Pulmonary Carcinoid Tumors
por: Taira, Naohiro, et al.
Publicado: (2014)

High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO(2)-Au Nanocomposite
por: Wei, Zheng, et al.
Publicado: (2019)

Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma
por: Cheng, Yizhuang, et al.
Publicado: (2019)

Effects of Bevacizumab Combined with Chemotherapy on CT, CyFRA21-1, and ProGRP and Prognosis of Lung Cancer Patients under Nursing Intervention
por: Xi, Chao, et al.
Publicado: (2022)

Retracted: Effects of Bevacizumab Combined with Chemotherapy on CT, CyFRA21-1, and ProGRP and Prognosis of Lung Cancer Patients under Nursing Intervention
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer
por: Zhang, Xiaozhu, et al.
Publicado: (2008)

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
por: Yufen, Xu, et al.
Publicado: (2016)

Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
por: Wang, Haocheng, et al.
Publicado: (2020)

ProGRP与NSE对小细胞肺癌诊断价值的meta分析
Publicado: (2010)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report
por: Fang, Guotao, et al.
Publicado: (2022)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
por: Phan, Thang Thanh, et al.
Publicado: (2019)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

血清NSE、ProGRP和LDH在小细胞肺癌诊断治疗中的作用
Publicado: (2016)

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
por: Sun, Wei, et al.
Publicado: (2015)

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
por: Chen, Yi, et al.
Publicado: (2023)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
por: Kogure, Yoshihito, et al.
Publicado: (2015)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy
por: Yu, Li, et al.
Publicado: (2022)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events
por: Sakata, Yoshihiko, et al.
Publicado: (2018)

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
por: Zhang, Zhimin, et al.
Publicado: (2020)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance
por: Liu, Detian, et al.
Publicado: (2023)

Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells
por: Wang, Jun, et al.
Publicado: (2022)

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
por: Li, Xin, et al.
Publicado: (2020)

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
por: ZHOU, BO, et al.
Publicado: (2016)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
por: Wang, Lingfei, et al.
Publicado: (2020)

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
por: Reita, Damien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1eesm2l4rg6ras8fjjir74593o